Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXC-201 vs Dara-CyBorD in Newly Diagnosed AL Amyloidosis
NCT07709715Phase 3Not yet recruiting
- Sponsor
- Nexcella
- Start
- Jan 2027
- Primary completion
- Dec 2028
01
Overview
A Phase 3 trial of NXC-201 in amyloid light chain amyloidosis (AL), sponsored by Nexcella. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
NXC-201
03
Conditions
amyloid light chain amyloidosis (AL)
Beyond the preview
Go deeper on NCT07709715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07709715.